NR4A1 and breast carcinoma: Although other agents, such as mTOR inhibitors, are effective for the therapy of different types of NENs, and are also approved, in combination with aromatase-inhibitors, for the treatment of hormone receptor positive advanced breast cancer, currently the use of everolimus has only been hypothesized for BNEN.